This site is intended for healthcare professionals only
DiabetesontheNet Logo
Sign In / Register

Issue:

Share this article

Which supplementation methods are effective for metformin-induced vitamin B12 deficiency?

Pam Brown
This systematic review confirms that supplementation with vitamin B12 in people with type 2 diabetes and metformin-induced deficiency is effective to prevent and treat B12 deficiency, although the impact of supplementation on existing neuropathy varied between studies. The studies included in the review demonstrate that both oral and parenteral supplementation can increase B12 levels and decrease serum homocysteine. Proposed pathways for development of metformin-associated B12 deficiency are explored as well as the impact on haematological and neurological pathways. Oral or sublingual methylcobalamin is recommended as the most effective, cost-effective and convenient method for supplementation in those requiring treatment. The authors call for more high-quality studies exploring optimal delivery methods and consideration of supplementation rather than periodic testing in those treated long-term with metformin to be discussed more widely in guidelines. This review provides useful information as we implement the MHRA guidance from June 2022 on identifying and managing metformin-induced B12 deficiency.

Vitamin B12 deficiency in those taking metformin has been known about since at least 1969; however, it has recently been identified to be more common than previously thought, prompting reviews of the existing literature and exploration of the most appropriate management options.

In this systematic review, Pratama and colleagues highlight the paucity of studies specifically in those with metformin-induced B12 deficiency and the lack of guidance on best approaches to supplementation for treatment or prevention. The article provides a helpful review of key papers exploring the mechanisms and timeframes of metformin-induced B12 deficiency, which can help us in the implementation of the MHRA guidance issued in June 2022.

Metformin may decrease intrinsic factor secretion from parietal cells, interfere with the calcium-dependent binding of the resulting intrinsic factor and B12 complex to receptors on the ileal lining, and change small intestinal motility, resulting in decreased B12 absorption. Metformin may also increase liver accumulation of B12, meaning it is less available, and it may alter reabsorption of bile acids, disrupting the enterohepatic circulation of B12. As well as causing B12 deficiency, an increase in methylmalonic acid occurs, which is thought to result in loss of myelin in the peripheral nerves and, consequently, neuropathy, which may be symptomatic as early as 2 years into metformin treatment.

There is around a 2.5-fold increase in B12 deficiency incidence in those treated with metformin, and this may occur as early as 3 months, although hepatic stores of vitamin B12 may take 5 years or more to deplete (Bell, 2022). In a previous randomised, placebo-controlled trial, de Jager et al (2010) added metformin 850 mg three times daily to insulin therapy (a higher metformin dose than is usually now used) and demonstrated a number needed to harm of just under 14 for development of B12 deficiency over the 4.3 years of the trial. Other studies have also confirmed that B12 deficiency increases with long-term use and is dose-dependent.

The authors express concern that there is not yet clear guidance on supplementation route and methods, and they discuss studies exploring this. A 1 mg intramuscular injection of hydroxocobalamin every 3 months is the commonest option in both studies and practice, and is recommended by NICE (2022a) in its guidance on management of B12 deficiency. Methylcobalamin is an active form of B12 which can be taken orally or sublingually, is retained longer in the body and has been studied for treatment of peripheral neuropathy. If oral therapy is trialled, check B12 levels at 8–12 weeks. Studies in this systematic review support B12 supplementation for the treatment or prevention of metformin-induced deficiency and neuropathy, demonstrating increased levels of B12 and decreased serum homocysteine with supplementation.

MHRA guidance

Metformin remains the first-line treatment option for most people with type 2 diabetes, including in the recently published ADA/EASD Consensus Report (Davies et al, 2022) and in the NICE (2022b) NG28 advice on type 2 diabetes management.

The MHRA (2022) recently issued guidance on the increased risk of vitamin B12 deficiency in people treated with metformin, highlighting increased risks with higher metformin doses, longer treatment duration and in patients with risk factors for B12 deficiency, including the following:

  • Existing low B12 levels.
  • People at risk of decreased absorption (elderly, inflammatory bowel disease, gastric resection or autoimmune conditions).
  • Strict vegan and some vegetarian diets.
  • Medications known to decrease B12 absorption (proton pump inhibitors, colchicine).

 

Clinicians are encouraged to test B12 levels in those presenting with anaemia or neuropathy, and to consider testing periodically in those with risk factors for deficiency. Those with low B12 may be asymptomatic, have symptoms of anaemia or neuropathy, or have glossitis, mouth ulcers, mental disturbances (depression, irritability, cognitive impairment). It is recommended that metformin treatment should continue while the B12 deficiency is corrected, in view of the drug’s known benefits in type 2 diabetes and its central role in treatment guidelines.

REFERENCES:

Bell DSH (2022) Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes Obes Metab 24: 1423–8

Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 24 Sep [Epub ahead of print]. https://doi.org/10.1007/s00125-022-05787-2

de Jager J, Kooy A, Lehert P et al (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 340: c2181

MHRA (2022) Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk. MHRA, London. Available at: https://bit.ly/3BlGkhJ (accessed 25.10.22)

NICE (2022a) Anaemia – B12 and folate deficiency: Clinical Knowledge Summary. NICE, London. Available at: https://bit.ly/3TRR4fl (accessed 25.10.22)

NICE 2022b) Type 2 diabetes in adults: management [NG28]. NICE, London. Available at: www.nice.org.uk/guidance/ng28 (accessed 25.10.22)

Related content
Dietary supplements are just not SPORTing for LDL-cholesterol reduction
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.